1. Home
  2. BANL vs APVO Comparison

BANL vs APVO Comparison

Compare BANL & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BANL

CBL International Limited

HOLD

Current Price

$0.41

Market Cap

10.2M

Sector

Energy

ML Signal

HOLD

Logo Aptevo Therapeutics Inc.

APVO

Aptevo Therapeutics Inc.

HOLD

Current Price

$4.51

Market Cap

8.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BANL
APVO
Founded
2015
2016
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Oil Refining/Marketing
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.2M
8.3M
IPO Year
2022
2023

Fundamental Metrics

Financial Performance
Metric
BANL
APVO
Price
$0.41
$4.51
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
180.4K
25.5K
Earning Date
04-17-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.13
EPS
N/A
N/A
Revenue
N/A
$3,114,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$0.50
52 Week High
$1.00
$13.11

Technical Indicators

Market Signals
Indicator
BANL
APVO
Relative Strength Index (RSI) 47.15 42.76
Support Level $0.40 $4.29
Resistance Level $0.47 $4.68
Average True Range (ATR) 0.04 0.28
MACD 0.00 -0.03
Stochastic Oscillator 50.18 9.53

Price Performance

Historical Comparison
BANL
APVO

About BANL CBL International Limited

CBL International Ltd is a marine fuel logistics company that provides a one-stop solution for vessel refueling. In the bunkering industry, it is referred to as a bunkering facilitator. It facilitates vessel refueling between ship operators and local physical distributors/traders by purchasing marine fuel, including fossil fuel and alternative fuel, from its suppliers and arranging for the suppliers to deliver the fuel to the customers. The company's customer base comprises container liners, bulk carriers, and tankers. Geographically, the company generates a majority of its revenue from China, followed by Hong Kong, Malaysia, Singapore, South Korea, and other regions.

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Share on Social Networks: